Phase 1/2 study evaluating the safety and efficacy of DSP‐7888 dosing emulsion in myelodysplastic syndromes

DSP‐7888 is an immunotherapeutic cancer vaccine derived from the Wilms’ tumor gene 1 (WT1) protein. This phase 1/2 open‐label study evaluated the safety and efficacy of DSP‐7888 dosing emulsion in patients with myelodysplastic syndromes (MDS). DSP‐7888 was administered intradermally (3.5 or 10.5 mg)...

Descripción completa

Detalles Bibliográficos
Autores principales: Ueda, Yasunori, Usuki, Kensuke, Fujita, Jiro, Matsumura, Itaru, Aotsuka, Nobuyuki, Sekiguchi, Naohiro, Nakazato, Tomonori, Iwasaki, Hiromi, Takahara‐Matsubara, Mariko, Sugimoto, Saori, Goto, Masashi, Naoe, Tomoki, Kizaki, Masahiro, Miyazaki, Yasushi, Aakashi, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990724/
https://www.ncbi.nlm.nih.gov/pubmed/34932235
http://dx.doi.org/10.1111/cas.15245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990724/
https://www.ncbi.nlm.nih.gov/pubmed/34932235
http://dx.doi.org/10.1111/cas.15245

Ejemplares similares